Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15114561 | 0.78 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL3985967 | 0.78 | FFAR3 (0.43) | FFAR3ALDH1A1 | |
| SCHEMBL15219976 | 0.78 | — | — | |
| SCHEMBL15482661 | 0.78 | SMN1; SMN2 (0.36) | ALDH1A1 | |
| SCHEMBL20697783 | 0.77 | — | — | |
| SCHEMBL1573844 | 0.74 | FFAR3 (0.40) | FFAR3ALDH1A1 | |
| SCHEMBL9613093 | 0.74 | FFAR3 (0.40) | FFAR3ALDH1A1 | |
| SCHEMBL24633933 | 0.74 | — | — | |
| SCHEMBL15482812 | 0.73 | — | — | |
| SCHEMBL3704763 | 0.73 | FFAR3 (0.39) | FFAR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | FFAR3 1630/4885ALDH1A1 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.